Strong Financial Position with ~$220 million cash and cash equivalents Returned Capital to Shareholders via Active Share Repurchase Program Introduced […]
– Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications – Company […]
CHANTILLY, Va., Aug. 16, 2024 (GLOBE NEWSWIRE) — Parsons Corporation (NYSE:PSN) announced today that it completed the previously announced acquisition […]